Stimulant Use and Study Protocol Completion: Assessing the Ability of Men Who Have Sex with Men to Collect Dried Blood Spots for Laboratory Measurement of HIV Viral Load.
Stimulant Use and Study Protocol Completion: Assessing the Ability of Men Who Have Sex with Men to Collect Dried Blood Spots for Laboratory Measurement of HIV Viral Load.
复制标题
兴奋剂的使用和研究方案的完成：评估男男性行为者收集干血点用于实验室测量 HIV 病毒载量的能力。
DOI：
10.1007/s10508-019-01515-x
复制
发表时间：
2020
影响因子：
3.8
通讯作者：
Hirshfield,Sabina
中科院分区：
文献类型：
--
作者：
Teran,RichardA;Carrico,AdamW;Horvath,KeithJ;DowningJr,MartinJ;Chiasson,MaryAnn;Walters,SuzanM;Hirshfield,Sabina
兴奋剂的使用与艾滋病毒载量（VL）和艾滋病毒性传播的风险较高的男男性行为者（MSM）艾滋病毒感染者。关于感染艾滋病毒的吸毒者是否愿意充分参与研究的研究很少，特别是那些涉及自我收集生物标志物数据的研究。本研究介绍了一项家庭干血斑采集研究的结果，该研究测量了报告高风险性行为和/或次优抗逆转录病毒治疗（ART）依从性的美国HIV阳性MSM中的实验室定量VL，以评估药物使用行为与（1）完成研究方案的能力和（2）VL结局之间的关联。在招募的参与者（n= 766）中，35%报告使用兴奋剂药物（安非他明，可卡因，快克，冰毒，摇头丸或兴奋剂药物的组合），39%报告使用其他药物（海洛因，大麻，处方阿片类药物等），27%报告在过去3个月内没有使用药物。总的来说，61%的入组参与者完成了研究方案。与其他药物使用者相比，兴奋剂使用者完成方案的可能性较小（ARR 0.84; 95% CI 0.72-0.98）。此外，其他吸毒者HIV VL结果≥ 1500拷贝/mL的可能性显著低于非吸毒者（ARR 0.52; 95% CI 0.28-0.97）。这项研究提供了重要的估计参与生物医学研究活动的可能性之间的艾滋病毒阳性的男男性接触者与不同的药物使用行为，表明它是可行的，进行这样的生物医学研究与药物使用的男男性接触者报告高风险的性行为和斗争与他们的ART坚持。
Stimulant use is associated with higher HIV viral load (VL) and sexual HIV transmission risk among men who have sex with men (MSM) living with HIV. There is little research on willingness of drug users living with HIV to fully participate in studies, especially those involving self-collection of biomarker data. This study presents findings from an at-home dried blood spot collection study measuring laboratory-quantified VL among U.S. HIV-positive MSM who reported high-risk sexual behavior and/or suboptimal antiretroviral therapy (ART) adherence to assess the association between drug-use behavior and (1) ability to complete a study protocol and (2) VL outcomes. Among recruited participants (n= 766), 35% reported stimulant drug use (amphetamines, cocaine, crack, crystal meth, ecstasy, or a combination of stimulant drugs), 39% reported using other drugs (heroin, marijuana, prescription opioids, and others), and 27% reported no drug use in the past 3 months. In all, 61% of enrolled participants completed the study protocol. Stimulant drug users were less likely (ARR 0.84; 95% CI 0.72–0.98) to complete the protocol than other drug users. Furthermore, other drug users were significantly less likely than non-drug users (ARR 0.52; 95% CI 0.28–0.97) to have an HIV VL result ≥ 1500 copies/mL. This study provides important estimates regarding the likelihood of participation in biomedical research activities among HIV-positive MSM with varying drug-use behaviors, showing that it is feasible to conduct such biomedical studies with drug-using MSM who report high-risk sexual behavior and struggle with their ART adherence.